Inactive Instrument

Aerie Pharmaceuticals, Inc.

AERI

US00771V1089

Aerie Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022

August 05, 2022 at 06:18 am

Aerie Pharmaceuticals, Inc. reported earnings results for the second quarter and six months ended June 30, 2022. For the second quarter, the company reported revenue was USD 33.31 million compared to USD 27.19 million a year ago. Net loss was USD 19.37 million compared to USD 38.69 million a year ago. Basic loss per share from continuing operations was USD 0.41 compared to USD 0.84 a year ago.
For the six months, revenue was USD 63.15 million compared to USD 50.16 million a year ago. Net loss was USD 55.26 million compared to USD 80.65 million a year ago. Basic loss per share from continuing operations was USD 1.16 compared to USD 1.75 a year ago.

Latest news about Aerie Pharmaceuticals, Inc.

Alcon Completes Acquisition of Aerie Pharmaceuticals for $930 Million	22-11-22	MT
Alcon Concludes $930 Million Purchase of US-based Aerie Pharmaceuticals	22-11-22	MT
Aerie Pharmaceuticals, Inc. Announces Executive Changes	22-11-21	CI
Aerie Pharmaceuticals, Inc. Announces Executive Changes	22-11-21	CI
Aerie Pharmaceuticals, Inc. Announces Management Changes	22-11-21	CI
Aerie Pharmaceuticals, Inc.(NasdaqGM:AERI) dropped from NASDAQ Composite Index	22-11-21	CI
Aerie Pharmaceuticals, Inc.(NasdaqGM:AERI) dropped from S&P TMI Index	22-11-21	CI
Aerie Pharmaceuticals, Inc.(NasdaqGM:AERI) dropped from S&P Global BMI Index	22-11-21	CI
Alcon Research, Ltd. completed the acquisition of Aerie Pharmaceuticals, Inc. from a group of shareholders.	22-11-20	CI
Aerie Pharmaceuticals, Inc.(NasdaqGM:AERI) dropped from NASDAQ Biotechnology Index	22-11-18	CI
Aerie Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-03	CI
Earnings Flash (AERI) AERIE PHARMACEUTICALS Reports Q3 Loss $-0.27	22-11-03	MT
Earnings Flash (AERI) AERIE PHARMACEUTICALS Posts Q3 Revenue $36.1M	22-11-03	MT
Transcript : Aerie Pharmaceuticals, Inc. - Special Call	22-09-23
North American Morning Briefing : Dow Futures Jump -2-	22-08-30	DJ
Citigroup Downgrades Aerie Pharmaceuticals to Neutral From Buy	22-08-29	MT
North American Morning Briefing : Stocks to Gain -2-	22-08-25	DJ
HC Wainwright Downgrades Aerie Pharmaceuticals to Neutral From Buy	22-08-24	MT
Sector Update: Health Care Stocks Declining in Late Trade	22-08-23	MT
Alcon to Acquire Aerie Pharmaceuticals in $770 Million Deal	22-08-23	MT
Sector Update: Health Care Stocks Dropping in Afternoon Trade	22-08-23	MT
Alcon to Acquire Aerie Pharmaceuticals in $770 Million Deal; Shares Rise Tuesday	22-08-23	MT
Truist Securities Downgrades Aerie Pharmaceuticals to Hold From Buy, Raises Price Target to $15.25 From $13	22-08-23	MT
Wall Street Stabilizes Pre-Bell After Slump Fueled by Rate Hike Concerns	22-08-23	MT
Sector Update: Health Care Stocks Mixed Premarket Tuesday	22-08-23	MT

Chart Aerie Pharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

Aerie Pharmaceuticals, Inc. is a pharmaceutical company. The Company is focused on the discovery, development and commercialization of ophthalmic therapies for the treatment of patients with eye diseases and conditions, including open-angle glaucoma, dry eye, diabetic macular edema (DME) and wet age-related macular degeneration (wet AMD). The Company's commercial products include Rhopressa and Rocklatan. Rhopressa is a once-daily eye drop designed to reduce elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. Rhopressa increases the outflow of aqueous humor through the trabecular meshwork (TM), which accounts for approximately 80% of fluid drainage from the healthy eye and is the diseased tissue responsible for elevated IOP in glaucoma. Rocklatan is a once-daily fixed-dose combination of Rhopressa and latanoprost, a drug for the treatment of patients with open-angle glaucoma or ocular hypertension.

Sector

Pharmaceuticals

More about the company

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ELI LILLY AND COMPANY	+37.74%	723B
NOVO NORDISK A/S	+32.22%	595B
JOHNSON & JOHNSON	-2.07%	369B
MERCK & CO., INC.	+20.25%	332B
ABBVIE INC.	+2.99%	282B
ASTRAZENECA PLC	+16.60%	244B
NOVARTIS AG	+9.77%	208B
ROCHE HOLDING AG	-5.15%	205B
AMGEN INC.	+7.43%	166B

Other Pharmaceuticals